Nivolumab Injectable Product

DRUG4 trials

Conditions

Ewing SarcomaGastric CancerHER-2 Protein OverexpressionHepatocellular CarcinomaKidney CancerOsteosarcomaPancreatic CancerPancreatic Ductal Adenocarcinoma

Phase 1

A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruitingNCT04477343

University of RochesterPancreatic Cancer, Pancreatic Ductal Adenocarcinoma

Start: 2020-11-23End: 2026-12-31Target: 20Updated: 2026-07-06

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

RecruitingNCT04995003

Baylor College of MedicineEwing Sarcoma, HER-2 Protein Overexpression, Osteosarcoma +5

Start: 2021-12-07End: 2043-06-30Target: 25Updated: 2026-01-22

Phase 2

Combination of TATE and PD-1 Inhibitor in Liver Cancer

RecruitingNCT03259867

Teclison Ltd.Gastric Cancer, Hepatocellular Carcinoma

Start: 2017-07-01End: 2027-06-30Target: 54Updated: 2026-04-16

Phase 4

A Study of Treatment Delivery Preference In People With Kidney Cancer

RecruitingNCT07872553

Memorial Sloan Kettering Cancer CenterKidney Cancer, Renal Cell Carcinoma

Start: 2026-09-24End: 2030-09-24Target: 40Updated: 2026-10-16

Related Papers

A phase 2, open-label single-arm, multi-center study of trans-arterial tirapazamine embolization (TATE) combined with nivolumab (nivo) in patients with advanced immunotherapy-refractory hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2026-01-10

A phase I study to evaluate the safety and tolerability of SX-682 in combination with PD-1 inhibitor as maintenance therapy for unresectable pancreatic adenocarcinoma.